Sangamo Therapeutics Inc Stock Price, News & Analysis

Sangamo Therapeutics (Nasdaq: SGMO) announced the FDA has accepted its request for a rolling submission and review of the Biologics License Application (BLA) for isaralgagene civaparvovec (ST-920) for adults with Fabry disease.

The FDA reiterated its prior agreement to use eGFR slope as an endpoint to support an accelerated approval pathway. Sangamo said the registrational Phase 1/2 STAAR study showed a positive mean annualized eGFR slope at 52 weeks across dosed patients and that the company plans to initiate rolling BLA submission later in Q4 2025. ST-920 holds multiple regulatory designations including Orphan Drug, Fast Track, RMAT, EMA PRIME and UK Innovative Licensing pathway.

Sangamo Therapeutics (Nasdaq: SGMO) reported Q3 2025 results and program updates on Nov 6, 2025. Key clinical highlights include detailed STAAR registrational data for isaralgagene civaparvovec (ST-920) in Fabry disease showing a positive mean annualized eGFR slope 1.965 mL/min/1.73m2/year at 52 weeks (n=32) and durability of α-Gal A activity up to 4.5 years. FDA reiterated use of eGFR slope to support an accelerated approval pathway; company preparing for a potential BLA as early as Q1 2026. Neurology updates: Phase 1/2 STAND enrollment started for ST-503 with first dosing expected in coming months; ST-506 CTA expected as early as mid-2026. Financials: Q3 net loss $34.9M, revenues $0.6M (vs $49.4M prior year), cash $29.6M as of Sept 30, 2025, with Nasdaq minimum bid extension to April 27, 2026.

Sangamo Therapeutics (NASDAQ: SGMO) announced it will release Q3 2025 financial results before the market opens on Thursday, November 6, 2025. The company will host a public conference call and webcast at 8:30 a.m. ET on November 6, 2025 to review results and provide business updates.

Participants should register in advance to receive a dial‑in number and unique passcode or use the dial‑out option; joining 10 minutes early is recommended. The live webcast link is available in the Investors and Media > Events section of the Sangamo website, and a replay will be posted after the call.

Sangamo Therapeutics (Nasdaq: SGMO) has presented detailed data from its registrational Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease. The study demonstrated a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year at 52 weeks across all 32 dosed patients.

Key highlights include stable cardiac function, sustained α-Gal A activity for up to 4.5 years, and successful withdrawal of all 18 patients from Enzyme Replacement Therapy (ERT). The therapy showed a favorable safety profile without requiring preconditioning, with mostly grade 1-2 adverse events.

Sangamo plans to submit a Biologics License Application (BLA) in Q1 2026 under the Accelerated Approval pathway. The therapy has received multiple regulatory designations, including Fast Track and RMAT from FDA.

Sangamo Therapeutics (Nasdaq: SGMO) reported significant progress in Q2 2025, highlighted by positive topline results from their registrational STAAR study for Fabry disease treatment. The study showed a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year at 52-weeks across all 32 patients, supporting potential FDA Accelerated Approval.

Financial results showed a reduced net loss of $20.0 million ($0.08 per share) compared to $36.1 million in Q2 2024. Revenues increased to $18.3 million, primarily from Eli Lilly's upfront license payment. Cash position stands at $38.3 million, expected to fund operations into Q4 2025.

The company initiated its first clinical site for the Phase 1/2 STAND study in chronic neuropathic pain, with first patient dosing expected fall 2025. Sangamo plans to submit a BLA for its Fabry disease treatment by Q1 2026.

Sangamo Therapeutics (Nasdaq: SGMO), a genomic medicine company, has scheduled its second quarter 2025 financial results release for Thursday, August 7, 2025, after market close. The company will host a conference call at 4:30 p.m. Eastern the same day to discuss financial results and provide business updates.

Participants can register and access the call through a provided link, with a recommended join time of 10 minutes before the event. The webcast will be available in the Investors and Media section of Sangamo's website, with a replay accessible after the call.

[]

Sangamo Therapeutics (Nasdaq: SGMO) announced positive topline results from its registrational Phase 1/2 STAAR study for isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease. The study demonstrated a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year at 52 weeks across all 32 patients, which will serve as the primary basis for FDA approval.

Key highlights include maintained elevated α-Gal A activity for up to 4.5 years, successful withdrawal of all 18 patients from enzyme replacement therapy (ERT), and significant improvements in quality of life scores. The therapy showed a favorable safety profile without preconditioning requirements. Sangamo plans to submit a Biologics License Application (BLA) in Q1 2026 under the Accelerated Approval pathway.

Sangamo Therapeutics (SGMO) reported Q1 2025 financial results and business updates. Key highlights include a new capsid license agreement with Lilly for CNS disease targets, receiving an $18M upfront fee with potential for $1.4B in additional milestone payments. The company achieved significant milestones in its Fabry disease program, with all patients completing 52-week follow-up required for FDA Accelerated Approval pathway. Q1 2025 financial results showed a net loss of $30.6M ($0.14/share), improved from $49.1M loss in Q1 2024. Revenues increased to $6.4M from $0.5M year-over-year. Cash position stands at $25.2M as of March 31, 2025. The company announced a $23M equity offering and expects current funds to support operations into Q3 2025. Sangamo continues to advance its neurology pipeline, including preparations for Phase 1/2 trials in chronic neuropathic pain and prion disease programs.

Sangamo Therapeutics (SGMO) has announced the pricing of a $23.0 million underwritten offering, consisting of 12,235,000 shares of common stock and pre-funded warrants for 34,398,393 shares, along with accompanying warrants to purchase 46,633,393 shares. The pricing is set at $0.50 per share with accompanying warrant, and $0.49 for each pre-funded warrant with accompanying warrant. The accompanying warrants have an exercise price of $0.75 per share, becoming exercisable after six months and expiring in six years. The offering is expected to close around May 14, 2025. Cantor is serving as the sole book-running manager, and Sangamo plans to use the proceeds for working capital and general corporate purposes.